Advancing Generic Drug Development: Translating Science to Approval 2024 (Day 2)
Рет қаралды 2,218
Күн бұрынJoin us for the 2024 Advancing Generic Drug Development Workshop! FDA experts will demonstrate the FDA’s Generic Drug User Fee Amendments (GDUFA) Science and Research Program’s transformative impact on generic drug development, regulation, and approval. Dissect complex scientific challenges in ANDAs alongside FDA experts, and gain insights into GDUFA III progress, GDUFA science and research on complex products and scientific issues to product-specific guidance development, pre-ANDA and ANDA meeting discussions. The workshop will also highlight innovative science and cutting-edge methodologies in generic drug development both within the U.S. and globally.
FDA D.I.S.C.O. Burst Edition: FDA approvals of Augtyro (repotrectinib) for NTRK gene fusion-posit...
U.S. Food and Drug Administration
Рет қаралды 1,9 М.
U.S. Food and Drug Administration
Рет қаралды 488
U.S. Food and Drug Administration
Рет қаралды 570
U.S. Food and Drug Administration
Рет қаралды 2,2 М.
FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) ...
U.S. Food and Drug Administration
Рет қаралды 2,6 М.
U.S. Food and Drug Administration
Рет қаралды 2,3 М.
U.S. Food and Drug Administration
Рет қаралды 1,6 М.
FDA D.I.S.C.O. Burst Edition: FDA approval of Retevmo (selpercatinib) for advanced or metastatic ...
U.S. Food and Drug Administration
Рет қаралды 2,5 М.
U.S. Food and Drug Administration
Рет қаралды 3 М.
U.S. Food and Drug Administration
Рет қаралды 610